# Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma

> **NCT01171482** · PHASE2 · TERMINATED · sponsor: **Seoul National University Hospital** · enrollment: 5 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** 5-FU
- **DRUG:** Mitomycin
- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT01171482
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** There were problems with national reimbursement policies.
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01171482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01171482, "Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01171482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*